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Abstract
Background: Only a small number of articles have investigated the relationship between mindfulness-based
interventions (MBIs) and biomarkers. The aim of this systematic review was to study the effect of MBIs on specific
biomarkers (cytokines, neuropeptides and C-reactive protein (CRP)) in both healthy subjects and cancer patients.
Methods: A search was conducted using PubMed, EMBASE, PsycINFO and the Cochrane library between 1980 and
September 2016.
Results: A total of 13 studies with 1110 participants were included. In the healthy population, MBIs had no effect
on cytokines, but were found to increase the levels of the neuropeptide insulin-like growth factor 1 (IGF-1). With
respect to neuropeptide Y, despite the absence of post-intervention differences, MBIs may enhance recovery from
stress. With regard to CRP, MBIs could be effective in lower Body Mass Index (BMI) individuals. In cancer patients,
MBIs seem to have some effect on cytokine levels, although it was not possible to determine which specific
cytokines were affected. One possibility is that MBIs might aid recovery of the immune system, increasing the
production of interleukin (IL)-4 and decreasing interferon gamma (IFN-γ).
Conclusions: MBIs may be involved in changes from a depressive/carcinogenic profile to a more normalized one.
However, given the complexity and different contexts of the immune system, and the fact that this investigation is
still in its preliminary stage, additional randomized controlled trials are needed to further establish the impact of
MBI programmes on biomarkers in both clinical and non-clinical populations.
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Background
The word “mindfulness” is the translation of sati (Pali)
or smṛiti (Sanskrit) into English. This is one of the most
essential concepts in Buddhism and could be translated
as “bare attention” or “present-centred awareness”, which
is intended to mean a sort of non-judgemental, non-
discursive attending to the here and now [1].
Mindfulness was first introduced into medical ser-
vices and society by Kabat-Zinn in the 1970s [2]. He de-
fined mindfulness as “paying attention in a particular
way, on purpose, in the present moment, and non-
judgementally”. The Mindfulness-Based Stress Reduction
(MBSR) programme, a treatment protocol to administer
mindfulness, was initially developed by Kabat-Zinn for
patients with chronic pain [3]. This programme has since
proved to be effective in treating not only healthy people
under stress but also patients with various types of
diseases: rheumatoid arthritis, ulcerative colitis, fibromyal-
gia, cancer, depression, post-traumatic stress disorder,
schizophrenia, and many more [4–10]. Other treatment
protocols using mindfulness have been developed that are
based on MBSR but with specific psychoeducational com-
ponents adapted to the target population. These protocols
are described as Mindfulness-Based Interventions (MBIs)
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and include, for example, Mindfulness-Based Cognitive
Therapy (MBCT), which is designed for major depression
patients under high risk of relapse and recurrence [11].
A large number of articles on mindfulness have been
published at a rapid rate in recent years. Williams and
Kabat-Zinn [11] showed that the number of publications
on mindfulness had reached 350 per year by 2010.
Although there are probably over 700 studies at this
point, only a small number of articles have investigated
the relationship between MBIs and biomarkers both in
healthy individuals and in patients with different disor-
ders, despite their potential relevance. For instance,
Matousek et al. [12] have reported the role of cortisol as
a physiological marker of improvement with respect to
MBSR. Moreover, there have only been two review studies
related to cancer or HIV patients [13, 14].
Aims
A systematic review was conducted with a specific focus
on cytokines, neuropeptides and C-reactive protein (CRP)
as biomarkers, because they are the most important and
well-researched biomarkers of inflammatory parameters
(except for cortisol, which has recently been reviewed in
other work [15]), and further permitting comparisons to
be made with previous studies. In addition, we classified
samples into two categories: healthy individuals and
cancer patients. Other disorders were not included in the
review owing to the few studies available to date, based on
a preliminary search. Thus, the aim of the present review
was to provide a summary of the relationships between
MBIs (MBSR is the most frequently used protocol but not
the only one) and biomarkers (focused on cytokines,
neuropeptides and CRP) both in healthy individuals and
in cancer patients.
Methods
We followed the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines [16]
and the recommendations of the Cochrane Collaboration
[17]. The protocol was registered with PROSPERO
(International Prospective Register of Systematic Reviews),
with registration number CRD42016042302.
Search
A search using PubMed, EMBASE, PsycINFO and the
Cochrane library was conducted by an expert in this
field (MSV). As an example, the searching strategy for
the PubMed database was the following:
((“Mindfulness”[Mesh] OR mindfulness OR
“mindfulness meditation” OR “meditation” OR
“mindfulness based cognitive therapy” OR MBCT
OR “mindfulness based stress reduction” OR MBSR))
AND (((((((“Cytokines”[Mesh]) OR
“Interleukins”[Mesh]) OR “Biological Markers”[Mesh])
OR “Neuropeptides”[Mesh]) OR “C-Reactive
Protein”[Mesh])) OR (((biomarker* OR cytokine* OR
interleukin* OR neuropeptide* OR “C-reactive
protein” OR CRP)))).
We included only studies published in English, French
and Spanish between January 1980 and September 2016.
The starting date was set because the first paper on
MBIs was published in 1982 [3]. The literature search
was conducted independently by two authors (KS and
MCPY). Disagreements between the authors were solved
by consensus, and when in doubt, the final decision was
made in consultation with a third author (JGC). We
followed standardized guidelines in order to enhance the
quality of reporting in the present selective review. The
last search was conducted on 04 October 2016.
Inclusion criteria
Studies were required to fulfil the conditions described
in the following sections [18].
Study designs
We included only the following experimental trials:
randomized controlled trials (RCTs), non-randomized
controlled trials (NRCTs), and open trials with a pre-
post analysis.
Participants
We included only studies with healthy individuals or
cancer patients. No restrictions were applied regarding
the number of participants. However, trials with mixed
types of participants (i.e. with cancer but also with
other disorders) and studies of patients with disorders
other than cancer were excluded. Examples of excluded
trials include Fang et al. [19] and Malarkey et al. [20].
The former was conducted in patients with chronic
pain but who also had depression and other disorders
(not declared a diagnostic tool), whereas the latter was
conducted in a workplace setting and most of the partici-
pants suffered from mild depression (nearly normal level),
diagnosed according to the Center for Epidemiological
Studies Depression (CES-D) that can measure depressive
symptomatology; i.e. depressive cognitions, affect, and
behaviours.
Biomarkers
We included only cytokines, neuropeptides and CRP as
biomarkers because these were the most frequently
studied biomarkers besides cortisol. Among the many
studies investigating cortisol and MBIs, an independent
paper on this biomarker has recently been published
[15]. Where articles included biomarkers other than
those targeted, they were included in the review, but
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only the findings related to the targeted biomarkers were
described.
Interventions
The MBSR programmes included in this review were
largely conducted in accordance with the standard
programme developed by Kabat-Zinn at the University
of Massachusetts Medical Center [2]. We also included
curricula adapted from the standard MBSR programme,
generally known as MBIs, such as MBCTand interventions
involving Mindfulness Meditation (MM) [21], Mindfulness
Training (MT) [22] and mindful awareness practices
(MAPs) [23]. We included only those programmes with a
minimum duration of 6 weeks because the effects of
shorter protocols (known as low-dose interventions)
should be studied independently owing to their own and
different features. An example of this type of protocol can
be found in Klatt et al. [24], and Creswell et al. [25].
Outcomes
Studies were judged eligible only if they assessed the re-
lationship between MBIs and biomarkers. We excluded
articles in which biomarkers were used as predictors to
identify the participants likely to benefit from the inter-
vention [26].
Accessibility of data
Only studies published as full papers were included.
Assessment of study quality
Risk of bias in the different types of study designs was
assessed with four criteria from the Cochrane Collabora-
tion’s tool [27]: 1) adequate generation of allocation
sequence; 2) concealment of allocation to conditions; 3)
prevention of knowledge of the allocated intervention;
and 4) dealing with incomplete outcome data. Studies
that met three or more criteria were considered to be of
high quality, and those that met fewer criteria were
judged to be of low quality [28, 29]. Quality of interven-
tions was evaluated according to three criteria [30]: use
of a treatment manual, provision of therapy by specifically
trained therapists, and verification of treatment integrity
during the study. Two reviewers (MD and MCPY) inde-
pendently assessed these criteria, and any discrepancies
were discussed with a third reviewer (JGC) for consensus.
Results
The search yielded a total of 570 records (Fig. 1), of
which 192 were duplicates. After screening the titles and
abstracts, 25 articles were assessed as full text. We finally
included 13 articles with a total of 1110 participants in this
paper. One of these articles [31] was conducted as a 1-
year follow-up study [32], and another two studies [33, 34]
were conducted with the same population. We divided
these trials into two categories based on the participant
characteristics: healthy individuals and cancer patients.
The figure displays the details of the study search and
selection process.
Healthy individuals
We included seven articles [21, 22, 33–37] with a total
of 750 healthy subjects. In most of these studies, the
proportion of female participants ranged between 60
and 80%, except for one study [22], which was con-
ducted on young male participants only. In two-thirds of
the included studies, the average age was over 60 years.
All of the studies were designed as RCTs, except one
[22], which was NRCT. Regarding intervention type, six
of the included studies were conducted with an 8-week
intervention (MBSR or MT programmes) consisting of
2–2.5 h of weekly group sessions and 30–60 min of daily
home practice. The remaining study [21] was imple-
mented with a 6-week MM intervention based on a 1.5-h
group session per week and daily home practice. We clas-
sified the seven included studies into the following two
groups based on biomarkers.
Cytokines
We included a total of six articles utilizing cytokines as
biomarkers. The characteristics of each study are shown
in Table 1. Five cytokines were included: Interleukin
(IL)-6, IL-8, tumour necrosis factor alpha (TNF-α) and
interferon gamma (IFN-γ), as pro-inflammatory cyto-
kines, and IL-10 as an anti-inflammatory cytokine. All of
these studies evaluated the effects of MBSR or MM
interventions on the above-mentioned cytokines. IL-6
was measured in three studies [21, 35, 36], IL-8 in two
studies [33, 37], TNF-α in two studies [21, 37], and IFN-γ
and IL-10 in one study [34].
For IL-6, three trials revealed no significant effects of
either MBSR or MM intervention, with no differences
found pre- and post-intervention [21, 35] or during
post-intervention follow-ups [32]. For IL-8, the results of
the two trials revealed discrepancies. Barrett et al. [33]
reported that the levels of IL-8 in nasal wash collected
during acute respiratory infection in the MBSR group
were slightly higher compared to those of the control
group (p = 0.022). In contrast, Rosenkranz et al. [37]
found no pre- and post-intervention differences in blister
fluid levels of IL-8 between the MBSR group and the ac-
tive comparison condition. For TNF-α, two trials [21, 37]
found no apparent pre- and post-intervention differences
in TNF-α levels between the different intervention condi-
tions; however, Rosenkranz et al. [37] reported that addi-
tional practice in the MBSR group was associated with
a decrease in TNF-α levels, whereas the active compari-
son group tended to show the opposite pattern. For
IFN-γ and IL-10, Hayney et al. [34] showed that there
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were no significant differences between the interven-
tion conditions in the production of these cytokines by
peripheral blood mononuclear cells (PBMCs) in influenza-
vaccinated individuals.
Neuropeptides and CRP
We included a total of four articles utilizing neuropep-
tides and CRP as biomarkers, three of which [21, 35, 36]
were also included in the group that utilized cytokines.
The characteristics of each study are shown in Table 2.
In terms of neuropeptides, there was one study of
insulin-like growth factor 1 (IGF-1) and neuropeptide Y
(NPY) [22, 36], and two studies on CRP [21, 35].
For IGF-1, increased practice of MBI activities over-
all was associated with significantly increased post-
intervention IGF-1 production, specifically with yoga
(p < 0.001) and sitting meditation (p < 0.01) [36]. For
NPY, the MT intervention group had lower concentra-
tions of this neuropeptide than the control group after
the stress reduction training (d = 0.33; p < 0.01);
however, there were no significant pre- and post-
intervention differences in plasma concentrations of
NPY between the MT intervention group and the
control group [22].
For CRP, the two above-mentioned trials showed in-
consistent findings. Creswell et al. [35] reported that the
MBSR group had marginal decreases in log-transformed
CRP compared to the control group (p = 0.075), with a
pre- and post-intervention effect size of d = 0.88 in the
MBSR group. In contrast, Oken et al. [21] found no sig-
nificant pre- and post-intervention differences in the
levels of CRP between the different intervention condi-
tions (p = 0.891).
Cancer patients
We included six articles (based on five studies) [23, 31,
32, 38–40], with a total of 360 participants. One of these,
by Carlson et al. [31], was conducted as a 1-year follow-
up study [32]. The characteristics of each study are
shown in Table 3. The average age of the patients in
these studies was in their 50s, with the exception of one
study [23], where the mean age of the patients was in
their 40s. The most frequent cancer type (total sample
n = 304) was breast cancer (90.8%), which was followed
Fig. 1 Algorithm of study selection (Following PRISMA guidelines)
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by prostate cancer (3.9%). Of these five studies, three trials
[23, 38, 40] recruited only breast cancer patients, although
the other two studies [32, 39] enrolled patients with mixed
types of cancer: breast and prostate cancers; and colon,
breast, lung and prostate cancers, respectively. No similar
criteria related to the duration of the cancer diagnosis
were found in the included studies. Carlson et al. [32] in-
cluded patients previously diagnosed with cancer for a
median of 1.1 years, and similarly, Bower et al. [23] in-
cluded patients diagnosed for a median of 4.0 years. There
were trials in the other studies that did not clearly describe
the duration of the cancer diagnosis, although Witek-
Janusek et al. [38] recruited patients with “recently” diag-
nosed breast cancer. Lengacher et al. [40] enrolled breast
cancer patients for whom a median time of 19 weeks had
passed since treatment completion. Many of the patients
in the selected articles had Stage I (44.4%) or Stage II
(26.7%) cancer, while Lengacher et al. [39] enrolled only
patients with Stage III (23.1%) or Stage IV (76.9%) cancer.
Bower et al. [23] did not declare the details of cancer
stage. There were differences in treatment regimen for the
study populations of each trial. Witek-Janusek et al. [38]
selected early-stage breast cancer patients who were
treated with breast-conserving surgery and did not receive
systemic chemotherapy. Lengacher et al. [40] examined
whether the type of cancer treatment influenced the rela-
tionship between treatment completion and lymphocyte
subset recovery. Bower et al. [23] included early-stage
breast cancer patients who had completed local and/or
adjuvant cancer therapy. The included articles consisted
of the three study design types: open trials [31, 32, 39],
RCTs [23, 40] and NRCTs [38].
With regard to the intervention characteristics, all of
the included studies were conducted with a 6- or 8-week
intervention involving MBSR or MAPs. Lengacher et al.
[39, 40] adapted the intervention into a 6-week MBSR
programme that included the entire content of the
standard 8-week programme developed by Kabat-Zinn
[2]. One of the studies [39] was conducted with group
sessions consisting of three live sessions and three at-
home practices for advanced-stage cancer patients.
Bower et al. [23] used a 6-week MAP programme at
UCLA (http://marc.ucla.edu). The other three studies
[31, 32, 38] were conducted with an 8-week MBSR inter-
vention providing 1.5–2.5 h of weekly group sessions in
accordance with the original standard [2].
All of the selected studies evaluated the effects of MBSR
or MAPs on cytokines and CRP as the biomarkers. Neuro-
peptides were not assessed. Four of the six trials examined
the levels of both pro- and anti-inflammatory cytokines,
while the remaining two trials [23, 39] evaluated IL-6 and
CRP, and IL-6 levels, respectively.
In relation to pro-inflammatory cytokines, three cyto-
kines were examined: IFN-γ, IL-6 and TNF. For IFN-γ,
the findings of four trials [31, 32, 38, 40] were in dis-
agreement. Although two trials showed that T cell pro-
duction of IFN-γ decreased substantially compared to
pre-intervention (d = 0.38; p < 0.01) [32], and across the 6-
and 12-month follow-up (d6 = 0.94; d12 = 1.00; p < 0.001)
[31], one trial [38] reported that the production of IFN-γ
in women by PBMCs in the MBSR group increased
significantly compared to that in the control group be-
tween the pre-intervention assessment and 1 month post-
intervention (p = 0.027). Another trial [40] reported that
phytohaemagglutinin-induced T cell production of IFN-γ
in the MBSR group did not change significantly between
pre- and post-intervention. For IL-6, Witek-Janusek et al.
[38] found that production of IL-6 by PBMCs in the
MBSR group was reduced with respect to the control
group between the pre-assessment and 1 month post-
intervention (p = 0.008). On the other hand, Lengacher et
al. [39] reported that a significant overall reduction in sal-
ivary IL-6 was observed in both patients and caregivers
from pre- to post-intervention. In a study performed by
Bower et al. [23], there was no significant effect of the
MAP intervention on IL-6 (p = 0.158). For TNF, only
one trial [31] was conducted, which showed that T
cell production of TNF decreased substantially between
pre-intervention and both the 6- and 12-month follow-up
(d6 = 0.92; d12 = 1.13; p < 0.001).
With respect to anti-inflammatory cytokines, two cy-
tokines were examined: IL-4 and IL-10. For IL-4, the
findings of four trials [31, 32, 38, 40] were in disagree-
ment. Carlson et al. [31] reported that IL-4 production
decreased between pre-intervention and the 6- and 12-
month follow-up (d6 = 1.01; d12 = 1.37; p < 0.001). Simi-
larly, two trials [38, 40] showed that IL-4 production in
the MBSR group decreased compared to that in the
control group between pre-assessment and 1 month
post-intervention [38] or post-intervention [40]. However,
the remaining trial [32] revealed that IL-4 production in-
creased significantly between pre- and post-intervention
(p < 0.01). For IL-10, two trials [32, 38] were conducted.
Carlson et al. [32] found that natural killer (NK) cell
production of IL-10 decreased between pre- and post-
intervention (d = 0.33; p < 0.01), while Witek-Janusek et
al. [38] showed that IL-10 production by PBMCs in the
MBSR group decreased with respect to the control
group between pre- and 1 month post-intervention
(p < 0.035).
For CRP, only one study [23] reported that no signifi-
cant effect was found from the MAP intervention on
CRP (p = 0.415).
Quality of included studies and interventions
With regard to risk of bias [27], seven studies were con-
sidered to be of high quality, and six were considered
low quality (Table 4) [27]. In relation to the quality of
Sanada et al. BMC Complementary and Alternative Medicine  (2017) 17:125 Page 8 of 13
the interventions, the use of a treatment manual was re-
ported in all trials, therapist training in eight trials, and
treatment integrity in none of the trials.
Discussion
To our knowledge, this is the first systematic review pro-
viding a summary of the relationships between MBIs
(MBSR and interventions involving MM, MT or MAPs)
and biomarkers, with a focus on cytokines, neuropep-
tides and CRP, in both healthy subjects and cancer
patients. We finally examined 12 articles (based on 13
studies) with a total of 1110 participants, which we di-
vided into two categories: healthy individuals and cancer
patients. None of the included studies could be con-
sidered to be of high quality, taking together into ac-
count the trial design, risk of bias and the quality of
interventions [27].
Healthy individuals
With respect to our seven selected articles (two studies
were conducted with the same sample), we should
consider the composition of participants and the char-
acteristics of the interventions. First, there was a re-
markable difference in the composition of men and
women. The proportion of female participants was
over 60% in many of the included studies. A second
finding is the relatively high mean age of the subjects;
more than half of the population were aged 60 years or
older. Future trials with a more balanced composition
of participants are needed. On the other hand, the in-
terventions were conducted using mainly an 8-week
programme (MBSR or MT) based on the standard de-
sign developed by Kabat-Zinn, with a 2–2.5-h group
session per week, although one study was conducted
with a 6-week MM intervention consisting of 1.5 h of
weekly group sessions.
Our findings in healthy individuals indicate that the
intervention programmes had no apparent effect on cy-
tokines: of the six articles, three studies [21, 35, 36] in-
vestigated the levels of IL-6 without finding significant
changes resulting from the interventions. Creswell et al.
[35] noted that the levels of IL-6 at baseline evaluation
were low because of the participants’ low risk of cardio-
vascular or inflammatory diseases. IL-6 is known to be
one of the earliest and more important mediators of the
induction of acute-phase protein synthesis [41], and it is
an important regulator of CRP production by the liver
[20]. Breines et al. [42] found that participants who were
higher in self-compassion showed significantly lower IL-
6 responses to acute psychosocial stressors. On the other
hand, some studies have reported that IL-6 may have
pro- or anti-inflammatory effects, depending on the cell
or tissue context [43]. Given this, it seems difficult to
evaluate the changes in IL-6 levels between pre- and
post-intervention.
Similarly, the study by Hayney et al. [34] concluded
that there were no significant differences in the produc-
tion of IFN-γ and IL-10 under the intervention conditions,
Table 4 Quality of included studies
Study Trial qualitya Intervention quality
Oken et al. (2010) [21] AS (+)
AC (+)
PK (+)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Barrett et al. (2012) [33] AS (+)
AC (+)
PK (-)
IO (+)
Manual (+)
Training (+)
Integrity check (?)
Creswell et al. (2012) [35] AS (+)
AC (+)
PK (-)
IO (+)
Manual (+)
Training (+)
Integrity check (?)
Gallegos et al. (2013) [36] AS (+)
AC (+)
PK (-)
IO (+)
Manual (+)
Training (?)
Integrity check (?)
Rosenkranz et al. (2013) [37] AS (+)
AC (+)
PK (+)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Hayney et al. (2014) [34] AS (+)
AC (+)
PK (+)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Johnson et al. (2014) [22] AS (+)
AC (+)
PK (-)
IO (+)
Manual (+)
Training (?)
Integrity check (?)
Carlson et al. (2003) [31] AS (-)
AC (-)
PK (-)
IO (+)
Manual (+)
Training (?)
Integrity check (?)
Carlson et al. (2007) [32] AS (-)
AC (-)
PK (-)
IO (+)
Manual (+)
Training (?)
Integrity check (?)
Witek-Janusek et al. (2008) [38] AS (-)
AC (-)
PK (-)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Lengacher et al. (2012) [39] AS (-)
AC (-)
PK (-)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Lengacher et al. (2013) [40] AS (+)
AC (+)
PK (-)
IO (?)
Manual (+)
Training (+)
Integrity check (?)
Bower et al. (2015) [23] AS (+)
AC (+)
PK (?)
IO (-)
Manual (+)
Training (?)
Integrity check (?)
AS adequate generation of allocation sequence, AC concealment of allocation,
PK prevention of knowledge of the allocated intervention, IO dealing with
incomplete outcome data
aRisk of bias: low (+), high (–), or unclear (?) [24]
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because it is more difficult to demonstrate improvements
resulting from any therapeutic intervention in healthy in-
dividuals. Of these cytokines, IFN-γ is known to be a pro-
inflammatory cytokine that is important for immunity
against viral and intracellular bacterial infections [14], and
it is mainly produced by T-helper (Th)1 and NK cells. IL-
10 is known to be an anti-inflammatory cytokine that re-
duces the production of IFN-γ, and it is mainly produced
by Th2 cells and monocytes.
The results for cytokines IL-8 and TNF-α were incon-
sistent. Of these cytokines, IL-8 is known to be a pro-
inflammatory cytokine that promotes the activation and
migration of neutrophils, and it is mainly produced by
macrophages and monocytes, among others. TNF-α is
known to be a typical pro-inflammatory cytokine that is
involved in protection against infection, and for its anti-
tumour effect. It is mainly produced by macrophages.
Future trials should evaluate the effects of MBIs on
cytokines using patients with different characteristics;
for example, participants who are younger, of a different
gender, or who have increased levels of CRP might be
used.
With respect to neuropeptides and CRP, our findings
revealed that the intervention programmes elicit a cer-
tain effect. For neuropeptides, the eligible studies in-
cluded one with IGF-1 and another with NPY. Gallegos
et al. [36] found that MBI activities, particularly yoga
and sitting meditation, were associated with significantly
higher levels of post-intervention IGF-1. IGF-1, also
known as somatomedin C, is known to be a growth fac-
tor that mediates cell growth and development. As these
techniques focus on breathing, emotional awareness,
and cognitive moment-by-moment awareness [36], in-
creased IGF-1 levels may therefore be related to the en-
hancement of cognitive function, and to cancer prevention.
Levine et al. [44] demonstrated that an increased protein
intake and the resulting increase in IGF-1 was associated
with reduced cancer in older adults, whereas a low protein
diet was likely to be useful for the prevention of cancer
during middle age.
Johnson et al. [22] reported that the MT intervention
had lower concentrations of NPY than the control group
after stressful training, although NPY levels did not sig-
nificantly differ between the groups, either at baseline or
at post-intervention. NPY is known to be a peptide
neurotransmitter that represents a protective factor in
the face of stress [45]. Previous studies showed that
higher levels of blood NPY in response to acute stress
predicted better performance during military training
[46], and less psychological distress [47]. In the study
conducted by Johnson et al. [22], the above-mentioned
finding suggests that MT intervention may have a bene-
ficial effect, enhancing recovery from stress; i.e. re-
sponses to stress may have been improved through MT
intervention. Finally, our findings for CRP indicated in-
consistent effects. Interestingly, however, Malarkey et al.
[20] reported a large body mass index (BMI) interaction
effect for CRP, although the participants included were
not only healthy individuals but also patients with mild
depression, according to the CES-D diagnosis. Future
trials should consider subjects with lower BMIs to better
evaluate the effects of MBIs on CRP.
Cancer patients
In cancer patients, our findings suggest that MBSR may
have some effect on the levels of cytokines, although we
could not determine which specific cytokines. This can
be said to promote immune homeostasis more rapidly.
Witek-Janusek et al. [38] reported that the reductions in
Th2 cytokines (IL-4, IL-6 and IL-10) may allow for
normalization of Th1 cytokines (e.g., IFN-γ), and Lenga-
cher et al. [40] showed that MBSR may confer some
beneficial effects on immune recovery. Another study
[31] identified that the changes in the immune profiles,
with increases in T cell production of IL-4, and decreases
in IFN-γ, were consistent with a shift in the balance from
a Th1 (pro-inflammatory) to a Th2 (anti-inflammatory)
environment. An increase in IFN-γ has often been ob-
served in subjects with depression [48], and increases in
IFN-γ and other TH1 type cytokines are associated with
pro-inflammatory effects. The cytokine pattern of depres-
sion has been comparable to that of cancer [48]. On the
other hand, IL-4 is known to be an anti-inflammatory
cytokine that promotes Th2 cell growth and differenti-
ation, and it is mainly produced by activated Th2 cells,
mast cells and natural killer T cells, among others. There-
fore, it seems to indicate that the immune changes might
show a shift away from a depressive/carcinogenic cytokine
profile to a more normalized one.
With regard to the conditions of the patients and the
characteristics of the interventions in our six selected ar-
ticles (based on five studies), no differences could be
found in the mean age of patients in any of the studies
except one, and many of the patients were in their 50s,
on average. In relation to the different cancers, the most
frequent type was breast cancer (90.8%). Of the included
five studies, three trials [23, 38, 40] were conducted
with only breast cancer patients; however, the other
two [32, 39] were with mixed types of cancer. Such as
diversity of cancer types may have a considerable com-
plicating effect for the interpretation of the relation-
ships between the interventions and cytokines because
of a gender difference. With regard to the duration of
the cancer diagnosis, there were several criteria in each
trial. Two trials [23, 32] included patients previously di-
agnosed with cancer for a median of 4.0, 1.1 years, re-
spectively. In the other studies, we were unable to find
a clear description; for example, one trial [38] recruited
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patients with “recently” diagnosed breast cancer. This
heterogeneity in the duration of the cancer diagnosis
may also have a significant complicating effect on the
interpretation of the relationship between the interven-
tions and cytokines. With respect to cancer stage and
treatment regimen, approximately 70% of the subjects
in the selected articles had Stage I or Stage II cancer,
and many of the trials recruited patients with early-
stage breast cancer, although one study [39] enrolled
only participants with Stage III or Stage IV cancer.
Treatment regimen largely depended on cancer stage.
Thus, some differences were observed in treatment
regimen for the study participants in each trial. One
study [38] included early-stage breast cancer patients
treated with breast-conserving surgery, not receiving
systemic chemotherapy. Another study [40] was con-
ducted on breast cancer survivors to examine whether
there was a difference in lymphocyte recovery as a
consequence of treatment regimen. Although the re-
sult was that lymphocyte recovery was generally con-
sistent irrespective of whether chemotherapy was used
in conjunction with radiation therapy, is recom-
mended that future trials should be based on the same
conditions.
There were several differences between the articles
concerning the characteristics of the interventions.
There were two MBSR treatment durations: either a 6-
or 8-week intervention, and there was also a MAP treat-
ment programme with a 6-week intervention. All of the
MBSR programmes were based on the standard protocol
produced by Kabat-Zinn [2], in which the duration of
the training is set at 8 weeks. Three trials [31, 32, 38]
were performed with an 8-week MBSR intervention; an-
other two trials [39, 40] involved a 6-week MBSR; and
the remainder [23] was with the described 6-week
programme of MAPs. In addition, with respect to the
substantive content of the MBSR programme, all but
one study [39] were conducted with 1.5–2.5 h of weekly
group sessions. A further-modified MBSR programme
that included three in-person sessions and three audio
sessions provided on CDs was also conducted for
advanced-stage cancer patients [39]. This training con-
sisted of three live sessions and three at-home prac-
tices. In line with this, future trials may require the
MBI programme to be varied in accordance with pa-
tients’ conditions, specifically for advanced-stage can-
cer patients.
Of note was the report by Matchim et al. [13], who
found that cytokine production (IFN-γ, TNF-α, and
IL-4) had a large effect size (greater than 1) at 6- and
12-month follow-ups post-MBSR in early-stage cancer
patients [31]. This result may indicate that further re-
search will require longitudinal studies to detect pos-
sible effects not clearly found so far.
Limitations
The primary limitation of this review was the small
number of included studies and their different and
limited quality designs, some of them with a high risk
of bias, and none with a clear evaluation of the inter-
vention integrity. Of the 13 articles, one study [31]
was a 1-year follow-up trial [32], while two studies
[33, 34] were conducted using the same population.
Our final inclusion trials were largely based on 11 arti-
cles. As far as quality is concerned, there were only
seven RCTs, including one small RCT [35] and one
pilot RCT [21].
Another limitation is the biased and heterogeneous
composition of the subjects. There were large bias in
gender and age in healthy individuals, whereas some
studies involving cancer patients were conducted using
participants with different conditions, specifically with
respect to the type and stage of cancer. In addition, the
descriptive parameters of the groups were not shown in
some studies [22, 33, 37, 38], and therefore, the recovery
of specific data in order to perform meta-analytic re-
views in the future will be difficult.
Additional limitations are related to methodological
problems. Biomarkers were examined in diverse mate-
rials: blood, nasal secretions, blister fluid and saliva.
Consequently, it is quite difficult to interpret the results
even though the same biomarker was compared. There
was also diversity with regard to the MBI programme
frequency and duration among the trials. Although it is
necessary to vary MBI training in accordance with the
participant’s situation, future trials would require the use
of MBI programmes with the same parameters in a more
or less homogeneous population.
Recommendations for future research
Above all, further studies should require rigorous RCT
designs. With respect to the MBI protocols, they should
be more homogeneous and include better descriptions if
they are to enable comparisons to be made. However,
the content of the MBIs could be varied depending on
the participant’s situation, provided that the basic com-
ponents are not changed.
In healthy individuals, the following provisions would
be beneficial for the conducting of future trials: 1) the
participants recruited should not only comprise older fe-
males but also young or adult males; 2) subjects with a
lower BMI or increased CRP level should also be en-
rolled; and 3) some neuropeptides or CRP, in addition to
cytokines, should also be taken into account as bio-
markers [49].
Similarly, in cancer patients, these following stipula-
tions would be of benefit: 1) the participants recruited
should be homogeneous, with similar conditions, par-
ticularly with respect to cancer type, cancer stage and
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treatment regimen; 2) trials with a follow-up period are
recommended; and 3) some neuropeptides should also
be included as biomarkers.
Conclusions
Despite a number of limitations, the results seem to in-
dicate that MBIs have no effect on cytokines in healthy
populations, probably owing to the balanced baseline
levels of pro- and anti-inflammatory cytokines in these
individuals. The most evident effect of MBIs in healthy
persons, particularly yoga and sitting meditation, was an
increase in post-intervention levels of the IGF-1 neuro-
peptide, an important biomarker related to cancer pre-
vention and other clinical conditions. For NPY, despite a
lack of post-intervention differences, MBIs may have a
beneficial effect on enhancing recovery from stress. Fi-
nally, the results were inconsistent for CRP, most likely
due to a large body mass index (BMI) interaction; MBIs
might be more effective in lower-BMI individuals.
With regard to cancer patients, the conclusion of this
study is that MBIs may have some effect on cytokines,
although it is not possible to determine on which spe-
cific cytokines. A plausible hypothesis to be contrasted
in future studies is that MBIs help the immune system
to normalize, increasing the production of Th2 cytokines
(e.g. IL-4), while reducing Th1 (e.g. IFN-γ) cytokines.
However, given the complexity and different contexts of
the immune system, and the fact that this investigation
is in its preliminary stage, additional randomized con-
trolled trials are needed to further establish the impact
of MBIs programmes on biomarkers, in both clinical
and non-clinical populations.
Abbreviations
BMI: Body mass index; BSI-18: Brief symptom inventory-18; CES-D: Center for
Epidemiological Studies Depression; CRP: C-reactive protein; IFN-γ: Interferon
gamma; IGF-1: Insulin-like growth factor 1; IL: Interleukin; MAPs: Mindfulness
awareness practices; MBCT: Mindfulness-based Cognitive Therapy;
MBIs: Mindfulness-Based Interventions; MBSR: Mindfulness-Based Stress
Reduction; MM: Mindfulness Meditation; MT: Mindfulness training;
NK: Natural killer; NPY: Neuropeptide Y; NRCTs: Non-randomized controlled
trials; PBMCs: Peripheral blood mononuclear cells; RCTs: Randomized
controlled trials; Th: T-helper; TNF-α: Tumour necrosis factor alpha
Acknowledgements
This study was financed by the Instituto de Salud Carlos III of the Spanish
Ministry of Economy and Competitiveness with the PI13/01637 grant titled
‘Eficacia y coste-efectividad de tres intervenciones psicológicas de baja inten-
sidad aplicadas por medio de TICs para el tratamiento de la depresión en
Atención Primaria: un estudio controlado’. The project also received funding
from the Network for Prevention and Health Promotion in primary Care
(RD12/0005) grant from the Instituto de Salud Carlos III of the Ministry of
Economy and Competitiveness (Spain), co-financed with European Union
ERDF funds.
Funding
There are no sources of funding to declare in this study.
Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.
Authors’ contributions
KS, MD, MG and JGC designed the project. MS, MCPY, JMM and MA collected
the data. All authors interpreted the results, drafted the manuscript and read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Aragon Health Sciences Institute (IACS), Zaragoza, Spain. 2Department of
Psychiatry, Showa University School of Medicine, Tokyo, Japan. 3The Primary
Care Prevention and Health Promotion Research Network (REDIAPP),
Barcelona, Spain. 4Department of Psychiatry, Miguel Servet University
Hospital, University of Zaragoza, Zaragoza, Spain. 5Department of Psychology
and Sociology, Faculty of Social and Human Sciences, University of Zaragoza,
Teruel, Spain. 6Department of Preventive Medicine, Federal University of Sao
Paulo (UNIFESP), “Mente Aberta” - Brazilian Centre for Mindfulness and
Health Promotion, Sao Paulo, Brazil. 7Hospital Israelita Albert Einstein, Sao
Paulo, Brazil. 8Faculty of Health Sciences and Sports, University of Zaragoza,
Huesca, Spain. 9Research Institute of Health Sciences (IUNICS), University of
Balearic Islands, Palma, Spain.
Received: 20 July 2016 Accepted: 16 February 2017
References
1. Sharf RH. Is mindfulness Buddhist? (and why it matters). Transcult Psychiatry.
2015;52(4):470-84. doi:10.1177/1363461514557561.
2. Kabat-Zinn J. Full catastrophe living: Using the wisdom of your body and
mind to face stress, pain and illness. New York: Delacorte; 1990.
3. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic
pain patients based on the practice of mindfulness meditation: theoretical
considerations and preliminary results. Gen Hosp Psychiatry. 1982;4(1):33–47.
4. Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finan P, Kratz A,
Parrish B, Irwin MR. Comparison of cognitive behavioral and mindfulness
meditation interventions on adaptation to rheumatoid arthritis for patients
with and without history of recurrent depression. J Consult Clin Psychol.
2008;76(3):408–21. doi:10.1037/0022-006X.76.3.408.
5. Jedel S, Hoffman A, Merriman P, Swanson B, Voigt R, Rajan KB, Shaikh M, Li
H, Keshavarzian A. A randomized controlled trial of mindfulness-based stress
reduction to prevent flare-up in patients with inactive ulcerative colitis.
Digestion. 2014;89(2):142–55. doi:10.1159/000356316.
6. Lauche R, Cramer H, Dobos G, Langhorst J, Schmidt S. A systematic
review and meta-analysis of mindfulness-based stress reduction for the
fibromyalgia syndrome. J Psychosom Res. 2013;75(6):500–10. doi:10.1016/j.
jpsychores.2013.10.010.
7. Cramer H, Lauche R, Paul A, Dobos G. Mindfulness-based stress reduction
for breast cancer-a systematic review and meta-analysis. Curr Oncol. 2012;
19(5):e343–52. doi:10.3747/co.19.1016.
8. Jain FA, Walsh RN, Eisendrath SJ, Christensen S, Rael Cahn B. Critical Analysis
of the Efficacy of Meditation Therapies for Acute and Subacute Phase
Treatment of Depressive Disorders: A Systematic Review. Psychosomatics
2014; 22. doi:10.1016/j.psym.2014.10.007.
9. Omidi A, Mohammadi A, Zargar F, Akbari H. Efficacy of mindfulness-based
stress reduction on mood States of veterans with post-traumatic stress
disorder. Arch Trauma Res. 2013;1(4):151–4. doi:10.5812/atr.8226.
10. Khoury B, Lecomte T, Gaudiano BA, Paquin K. Mindfulness interventions for
psychosis: a meta-analysis. Schizophr Res. 2013;150(1):176–84. doi:10.1016/j.
schres.2013.07.055.
11. Williams JMG, Kabat-Zinn J. Mindfulness: diverse perspectives on its meaning,
origins, and multiple applications at the intersection of science and dharma.
Contemporary Buddhism. 2011;12(1):1–18. doi:10.1080/14639947.2011.564811.
12. Matousek RH, Dobkin PL, Pruessner J. Cortisol as a marker for improvement
in mindfulness-based stress reduction. Complement Ther Clin Pract. 2010;
16(1):13–9. doi:10.1016/j.ctcp.2009.06.004.
Sanada et al. BMC Complementary and Alternative Medicine  (2017) 17:125 Page 12 of 13
13. Matchim Y, Armer JM, Stewart BR. Mindfulness-based stress reduction
among breast cancer survivors: a literature review and discussion. Oncol
Nurs Forum. 2011;38(2):E61–71. doi:10.1188/11.ONF.E61-E71.
14. Lerner RZ, Kibler JL, Zeichner SB. Relationship Between Mindfulness-Based
Stress Reduction and Immune Function in Cancer and HIV/AIDS. Cancer
Clin Oncol. 2013; 2(1). doi:10.5539/cco.v2n1p62.
15. Sanada K, Montero-Marin J, Alda M, Salas-Valero M, Perez-Yus M, Morillo H,
Demarzo M, Garcia-Toro M, Garcia-Campayo J. Effects of Mindfulness-based
interventions on salivary cortisol in healthy adults: a meta-analytical review.
Front Physiol. 2016;7:471. doi:10.3389/fphys.2016.00471.
16. Moher D, Liberati A, Tetzlaff J. Altman DG; PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. Int J Surg. 2010;8(5):336–41.
17. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
Interventions. Version 5.1.0. http://handbook.cochrane.org/. Updated March
2011. Accessed 14 Apr 2015.
18. Shamseer L, Moher D, Clarke M, Ghersi D, Deceased LA, Petticrew M,
Shekelle P, Stewart LA, the PRISMA-P Group. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration
and explanation. BMJ. 2015;349:g7647. doi:10.1136/bmj.g7647.
19. Fang CY, Reibel DK, Longacre ML, Rosenzweig S, Campbell DE, Douglas SD.
Enhanced psychosocial well-being following participation in a mindfulness-based
stress reduction program is associated with increased natural killer cell activity.
J Altern Complement Med. 2010;16(5):531–8. doi:10.1089/acm.2009.0018.
20. Malarkey WB, Jarjoura D, Klatt M. Workplace based mindfulness practice and
inflammation: a randomized trial. Brain Behav Immun. 2013;27(1):145–54.
doi:10.1016/j.bbi.2012.10.009.
21. Oken BS, Fonareva I, Haas M, Wahbeh H, Lane JB, Zajdel D, Amen A. Pilot
controlled trial of mindfulness meditation and education for dementia caregivers.
J Altern Complement Med. 2010;16(10):1031–8. doi:10.1089/acm.2009.0733.
22. Johnson DC, Thom NJ, Stanley EA, Haase L, Simmons AN, Shih PA,
Thompson WK, Potterat EG, Minor TR, Paulus MP. Modifying resilience
mechanisms in at-risk individuals: a controlled study of mindfulness training
in Marines preparing for deployment. Am J Psychiatry. 2014;171(8):844–53.
doi:10.1176/appi.ajp.2014.13040502.
23. Bower JE, Crosswell AD, Stanton AL, Crespi CM, Winston D, Arevalo J, Ma J,
Cole SW, Ganz PA. Mindfulness meditation for younger breast cancer
survivors: a randomized controlled trial. Cancer. 2015;121(8):1231–40.
doi:10.1002/cncr.29194.
24. Klatt MD, Buckworth J, Malarkey WB. Effects of low-dose mindfulness-based
stress reduction (MBSR-ld) on working adults. Health Educ Behav. 2009;36(3):
601–14. doi:10.1177/10901981108317627.
25. Creswell JD, Taren AA, Lindsay EK, Greco CM, Gianaros PJ, Fairgrieve A,
Marsland AL, Brown KW, Way BM, Rosen RK, Ferris JL. Alterations in Resting-
State Functional Connectivity Link Mindfulness Meditation With Reduced
Interleukin-6: A Randomized Controlled Trial. Biol Psychiatry. 2016;80(1):53–61.
doi:10.1016/j.biopsych.2016.01.008.
26. Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen
RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Baseline
immune biomarkers as predictors of MBSR(BC) treatment success in off-
treatment breast cancer patients. Biol Res Nurs. 2014;16(4):429–37.
doi:10.1177/1099800413519494.
27. Higgins JPT, Altman DG, Gotzsche PC, Cochrane Bias Methods Group;
Cochrane Statistical Methods Group. he Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
28. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G.
Psychological treatment of generalized anxiety disorder: a metaanalysis. Clin
Psychol Rev. 2014;34(2):130–40.
29. Demarzo MM, Montero-Marin J, Cuijpers P, Zabaleta-del-Olmo E, Mahtani
KR, Vellinga A, Vicens C, López-del-Hoyo Y, García-Campayo J. The Efficacy
of Mindfulness-Based Interventions in Primary Care: A Meta-Analytic Review.
Ann Fam Med. 2015;13(6):573–82. doi:10.1370/afm.1863.
30. Chambless DL, Hollon SD. Defining empirically supported therapies. J Consult
Clin Psychol. 1998;66(1):7–18.
31. Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention
follow-up of psychological, immune, endocrine and blood pressure
outcomes of mindfulness-based stress reduction (MBSR) in breast and
prostate cancer outpatients. Brain Behav Immun. 2007;21(8):1038–49.
32. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in
relation to quality of life, mood, symptoms of stress, and immune parameters
in breast and prostate cancer outpatients. Psychosom Med. 2003;65(4):571–81.
33. Barrett B, Hayney MS, Muller D, Rakel D, Ward A, Obasi CN, Brown R, Zhang Z,
Zgierska A, Gern J, West R, Ewers T, Barlow S, Gassman M, Coe CL. Meditation
or exercise for preventing acute respiratory infection: a randomized controlled
trial. Ann Fam Med. 2012;10(4):337–46. doi:10.1370/afm.1376.
34. Hayney MS, Coe CL, Muller D, Obasi CN, Backonja U, Ewers T, Barrett B. Age
and psychological influences on immune responses to trivalent inactivated
influenza vaccine in the meditation or exercise for preventing acute
respiratory infection (MEPARI) trial. Hum Vaccin Immunother. 2014;10(1):83–91.
doi:10.4161/hv.26661.
35. Creswell JD, Irwin MR, Burklund LJ, Lieberman MD, Arevalo JM, Ma J,
Breen EC, Cole SW. Mindfulness-Based Stress Reduction training reduces
loneliness and pro-inflammatory gene expression in older adults: a small
randomized controlled trial. Brain Behav Immun. 2012;26(7):1095–101.
doi:10.1016/j.bbi.2012.07.006.
36. Gallegos AM, Hoerger M, Talbot NL, Krasner MS, Knight JM, Moynihan JA,
Duberstein PR. Toward identifying the effects of the specific components of
Mindfulness-Based Stress Reduction on biologic and emotional outcomes
among older adults. J Altern Complement Med. 2013;19(10):787–92.
doi:10.1089/acm.2012.0028.
37. Rosenkranz MA, Davidson RJ, Maccoon DG, Sheridan JF, Kalin NH, Lutz A. A
comparison of mindfulness-based stress reduction and an active control in
modulation of neurogenic inflammation. Brain Behav Immun. 2013;27(1):
174–84. doi:10.1016/j.bbi.2012.10.013.
38. Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R,
Mathews HL. Effect of mindfulness based stress reduction on immune function,
quality of life and coping in women newly diagnosed with early stage breast
cancer. Brain Behav Immun. 2008;22(6):969–81. doi:10.1016/j.bbi.2008.01.012.
39. Lengacher CA, Kip KE, Barta M, Post-White J, Jacobsen PB, Groer M, Lehman B,
Moscoso MS, Kadel R, Le N, Loftus L, Stevens CA, Malafa MP, Shelton MM. A pilot
study evaluating the effect of mindfulness-based stress reduction on psychological
status, physical status, salivary cortisol, and interleukin-6 among advanced-stage
cancer patients and their caregivers. J Holist Nurs. 2012;30(3):170–85.
40. Lengacher CA, Kip KE, Post-White J, Fitzgerald S, Newton C, Barta M, Jacobsen
PB, Shelton MM, Moscoso M, Johnson-Mallard V, Harris E, Loftus L, Cox C, Le N,
Goodman M, Djeu J, Widen RH, Bercu BB, Klein TW. Lymphocyte recovery after
breast cancer treatment and mindfulness-based stress reduction (MBSR)
therapy. Biol Res Nurs. 2013;15(1):37–47. doi:10.1177/1099800411419245.
41. Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and
cytokines. Immunol Lett. 2014;161(2):200–3. doi:10.1016/j.imlet.2014.01.009.
42. Breines JG, Thoma MV, Gianferante D, Hanlin L, Chen X, Rohleder N. Self-
compassion as a predictor of interleukin-6 response to acute psychosocial
stress. Brain Behav Immun. 2014;37:109–14. doi:10.1016/j.bbi.2013.11.006.
43. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S,
Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A,
Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC. Signaling by
IL-6 promotes alternative activation of macrophages to limit endotoxemia
and obesity-associated resistance to insulin. Nat Immunol. 2014;15(5):423–30.
doi:10.1038/ni.2865.
44. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F,
Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK,
Wei M, Cohen P, Crimmins EM, Longo VD. Low protein intake is associated
with a major reduction in IGF-1, cancer, and overall mortality in the 65 and
younger but not older population. Cell Metab. 2014;19(3):407–17. doi:10.
1016/j.cmet.2014.02.006.
45. Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of
resilience. Nat Neurosci. 2012;15(11):1475–84. doi:10.1038/nn.3234.
46. Morgan 3rd CA, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger
RL, Charney DS. Plasma neuropeptide-Y concentrations in humans
exposed to military survival training. Biol Psychiatry. 2000;47(10):902–9.
doi:10.1016/S0006-3223(99)00239-5.
47. Morgan 3rd CA, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G.
Neuropeptide-Y, cortisol, and subjective distress in humans exposed to
acute stress: replication and extension of previous report. Biol Psychiatry.
2002;52(2):136–42. doi:10.1016/S0006-3223(02)01319-7.
48. Holden RJ, Pakula IS, Mooney PA. An immunological model connecting the
pathogenesis of stress, depression and carcinoma. Med Hypotheses. 1998;
51(4):309–14. doi:10.1016/S0306-9877(98)90054-8.
49. Gómez-Alcaina B, Montero-Marín J, Demarzo MMP, Pereira JP, García-
Campayo J. Utilidad de los marcadores biológicos en la detección precoz y
prevención del síndrome de burnout. Revista de Psicopatología y Psicología
Clínica. 2013;18(3):245–53.
Sanada et al. BMC Complementary and Alternative Medicine  (2017) 17:125 Page 13 of 13
